Last updated: September 9, 2026
RIXUBIS is a recombinant factor IX product for hemophilia B developed by Baxter and later commercialized through Baxalta, Shire, and Takeda. The product received U.S. FDA approval in December 2013. Its commercial position has weakened as the hemophilia B market shifted toward extended-half-life factor IX products, subcutaneous non-factor therapies, and gene therapy. Takeda does not report RIXUBIS revenue as a standalone line item, preventing a precise public sales trajectory. The principal commercial risks are product substitution, portfolio rationalization, and potential biosimilar competition after biologic exclusivity expires.
What is RIXUBIS and how is it used?
RIXUBIS is a recombinant coagulation factor IX, or factor IX recombinant, indicated for adults and children with hemophilia B caused by congenital factor IX deficiency. It is administered intravenously for:
- On-demand treatment and control of bleeding episodes
- Perioperative management
- Routine prophylaxis to reduce bleeding frequency
The product is manufactured using recombinant technology and does not contain human blood-derived proteins in the final formulation. The U.S. product is supplied as a lyophilized powder for reconstitution in several nominal dosage strengths. The FDA-approved label identifies RIXUBIS as a conventional half-life factor IX product rather than an extended-half-life therapy. [1]
RIXUBIS entered the U.S. market during a period when standard-half-life recombinant factor IX products were established treatments but faced growing pressure from longer-acting alternatives.
When did RIXUBIS receive FDA approval and lose regulatory exclusivity?
RIXUBIS received FDA approval on December 23, 2013, under biologics license application BLA 125354. [1]
| Regulatory milestone |
Date or status |
| U.S. FDA approval |
December 23, 2013 |
| BLA |
125354 |
| Orphan-drug exclusivity |
Approximately seven years from approval, subject to the orphan designation scope |
| BPCIA reference-product data exclusivity |
Approximately 12 years from approval |
| Estimated U.S. reference-product exclusivity endpoint |
December 23, 2025 |
| U.S. biosimilar approval status |
No RIXUBIS biosimilar identified in the FDA Purple Book through the latest publicly available listings reviewed |
| FDA regulatory category |
Licensed biologic |
The 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act is separate from patent protection. It blocks approval of a biosimilar application relying on RIXUBIS data during the exclusivity period, but it does not necessarily prevent a competitor from relying on its own data or launching after patent expiry if no enforceable patent barrier remains. [2]
RIXUBIS is regulated as a biologic rather than a small-molecule drug. Its principal U.S. regulatory reference is therefore the FDA Purple Book, not the Orange Book. The product does not have the conventional Orange Book patent-listing framework used for small-molecule medicines. [3]
What patents protect RIXUBIS?
Publicly available U.S. regulatory materials do not provide a complete, definitive list of every patent that may cover RIXUBIS, its manufacturing process, formulation, or approved uses. Unlike small-molecule products, RIXUBIS does not have a standard Orange Book patent listing that presents the commercial patent estate in one consolidated record.
The potentially relevant protection categories include:
- Recombinant factor IX production methods
- Cell-line and expression-system technology
- Purification and viral-clearance processes
- Formulation and stability technology
- Manufacturing controls and analytical methods
- Product-specific clinical and dosing methods
The core commercial protection for RIXUBIS has historically come from regulatory exclusivity, manufacturing know-how, quality systems, and the difficulty of reproducing a complex biologic. The product’s patent position is less transparent than that of an orally administered chemical drug.
How strong is the RIXUBIS patent estate?
The publicly visible patent estate appears less commercially decisive than the patent estates surrounding newer factor IX products and gene therapies. RIXUBIS is based on a conventional recombinant factor IX platform, and its competitive position depends heavily on manufacturing consistency, treatment-center adoption, reimbursement, and supply reliability.
A competitor seeking to enter with a biosimilar or interchangeable product would face analytical, clinical, manufacturing, and regulatory barriers. Those barriers can delay entry even when patent protection is limited. They do not create permanent exclusivity.
No major publicly reported U.S. Paragraph IV litigation directed specifically at RIXUBIS has established a material litigation barrier to entry. Because biologic competitors use the BPCIA pathway rather than the traditional ANDA Paragraph IV mechanism, the more relevant legal process would involve patent-disclosure and patent-litigation procedures under the biosimilar patent dance.
What is the Orange Book and Purple Book status of RIXUBIS?
RIXUBIS is not a conventional Orange Book product. The FDA Purple Book is the relevant database because RIXUBIS is a licensed biologic. [3]
The product’s regulatory position can be summarized as follows:
| Issue |
RIXUBIS status |
| Orange Book reference product |
No |
| Purple Book biologic |
Yes |
| BLA reference product |
Yes |
| Small-molecule ANDA pathway |
No |
| Biosimilar pathway |
BPCIA |
| Interchangeability designation |
No publicly identified designation |
| Standalone Orange Book patent listing |
Not applicable |
The absence of an Orange Book listing does not mean RIXUBIS has no intellectual-property protection. It means the product is governed by the biologic patent and exclusivity framework.
How has the RIXUBIS market changed?
The hemophilia B market has moved away from conventional factor IX products. Four changes have had the greatest effect.
Extended-half-life factor IX products
Products such as Alprolix, Idelvion, and Rebinyn allow longer dosing intervals or higher sustained factor levels than standard-half-life products. Their commercial value is based on reducing infusion frequency, improving adherence, and supporting higher trough-factor targets.
RIXUBIS competes with:
- Benefix, a standard-half-life recombinant factor IX from Pfizer
- Alprolix, an extended-half-life factor IX Fc fusion protein from Sanofi and Sobi
- Idelvion, an albumin-fusion recombinant factor IX from CSL Behring
- Rebinyn, a glycoPEGylated recombinant factor IX from Novo Nordisk
- Plasma-derived factor IX products
- Hemgenix, an adeno-associated virus gene therapy from CSL Behring
Gene therapy
Hemgenix was approved by the FDA in November 2022 for adults with hemophilia B who use factor IX prophylaxis, have current or historical life-threatening hemorrhage, or have repeated serious spontaneous bleeding and lack neutralizing antibodies to the AAV5 vector. [4]
Hemgenix carries a high one-time treatment price but competes with chronic factor replacement over the long term. Its use is constrained by eligibility, liver-related monitoring, vector immunity, durability questions, manufacturing capacity, and payer authorization. It is not an immediate replacement for all RIXUBIS patients, but it changes treatment-center discussions and payer economics.
Non-factor prophylaxis
The hemophilia B market remains more dependent on factor replacement than hemophilia A, where emicizumab has materially changed prophylaxis. Even so, non-factor approaches and investigational therapies are increasing competitive pressure. Patients and physicians increasingly assess bleeding protection, administration burden, total annual factor consumption, and quality of life rather than product price alone.
Purchasing and reimbursement pressure
Hemophilia medicines are commonly purchased through specialty pharmacies, hospital systems, hemophilia treatment centers, and public or private payers. Contracting and preferred-product decisions can shift market share between factor IX brands. Manufacturers with broader hematology portfolios can use distribution, patient-support programs, and contracting infrastructure to defend volume.
What is the financial trajectory of RIXUBIS?
RIXUBIS revenue is not separately disclosed in the public financial reporting of Baxter, Baxalta, Shire, or Takeda. Reported figures generally combine RIXUBIS with other hematology products, recombinant factor products, or broader business segments.
The ownership and reporting history is:
| Period |
Commercial owner or parent |
Financial reporting context |
| 2013-2015 |
Baxter |
RIXUBIS launched within Baxter’s hemophilia portfolio |
| 2015-2016 |
Baxalta |
Baxalta became an independent Baxter spin-off |
| 2016-2019 |
Shire |
Shire acquired Baxalta |
| 2019-present |
Takeda |
Takeda acquired Shire |
Baxalta was acquired by Shire in a transaction valued at approximately $32 billion. Takeda completed its acquisition of Shire in January 2019 for approximately $59 billion. These transactions transferred the product between corporate portfolios but did not establish a disclosed RIXUBIS-specific valuation. [5][6]
Revenue exposure and commercial interpretation
RIXUBIS appears to have become a small component of the broader hematology businesses after the launch of extended-half-life competitors. Takeda’s public reporting has not provided a standalone RIXUBIS revenue series, making the following conclusions supportable:
- RIXUBIS is not a separately material reported revenue driver for Takeda.
- Product-level growth, decline, and margin cannot be calculated from public annual reports.
- Any valuation model using RIXUBIS revenue must rely on estimates rather than company-reported figures.
- The product’s financial importance is more likely tied to portfolio breadth and treatment-center relationships than to a major standalone growth franchise.
- The product faces long-term volume erosion from extended-half-life factor IX, gene therapy, and contracting pressure.
Takeda’s 2024 corporate reporting emphasized portfolio transformation, cost control, and growth products rather than RIXUBIS-specific expansion. [7]
Which companies are challenging RIXUBIS commercially?
The main competitive threats are established manufacturers with differentiated factor IX products and gene-therapy capabilities.
| Competitor |
Company |
Product type |
Competitive effect |
| Benefix |
Pfizer |
Standard-half-life recombinant factor IX |
Direct conventional-factor competitor |
| Alprolix |
Sanofi/Sobi |
Extended-half-life factor IX Fc fusion |
Reduces infusion frequency |
| Idelvion |
CSL Behring |
Albumin-fusion factor IX |
Longer protection and prophylaxis differentiation |
| Rebinyn |
Novo Nordisk |
GlycoPEGylated factor IX |
Extended-half-life positioning |
| Hemgenix |
CSL Behring |
AAV5 gene therapy |
Potential one-time alternative for eligible adults |
| Plasma-derived factor IX |
Multiple suppliers |
Plasma-derived replacement |
Price, supply, and physician preference competition |
The strongest direct commercial threat comes from extended-half-life products. Biosimilar competition is a later-stage risk because no RIXUBIS biosimilar has established a visible U.S. commercial position in the available regulatory record.
What patent litigation, Paragraph IV challenges, or settlements affect RIXUBIS?
No major publicly reported U.S. Paragraph IV challenge or settlement has been identified as a central RIXUBIS market event. Paragraph IV is primarily an abbreviated new drug application mechanism for small-molecule generics and is not the standard route for a biologic such as RIXUBIS.
For a biosimilar entrant, the relevant issues would include:
- BPCIA patent-exchange procedures
- Patent claims covering manufacturing or formulation
- Patent infringement litigation under 35 U.S.C. § 271(e)(2)
- FDA approval timing after biologic reference-product exclusivity
- Interchangeability requirements, if pursued
- Manufacturing comparability and analytical similarity
The absence of a prominent public settlement does not eliminate future biosimilar patent risk. It indicates that no major disclosed legal event has yet materially altered the product’s commercial timeline.
What generic or biosimilar entry risks exist for RIXUBIS?
RIXUBIS does not face ordinary generic entry. The relevant threat is a biosimilar or, potentially, a competing recombinant factor IX product developed under an independent biologic pathway.
Near-term entry risk is moderated by:
- Complex manufacturing requirements
- Need for extensive analytical comparability
- Limited patient population
- Treatment-center and payer switching barriers
- Product-specific immunogenicity and potency evaluation
- Potential process and manufacturing patents
- Regulatory and commercial costs
Longer-term entry risk is higher because the 12-year U.S. reference-product exclusivity period is expected to end in December 2025. A biosimilar may still require several additional years to complete development, secure approval, resolve patent issues, and obtain payer access.
The more immediate risk is therapeutic substitution by existing extended-half-life products rather than rapid price erosion from a RIXUBIS biosimilar.
How does RIXUBIS compare with extended-half-life factor IX products?
| Attribute |
RIXUBIS |
Extended-half-life factor IX products |
| Product class |
Recombinant factor IX |
Recombinant modified factor IX |
| Dosing burden |
Conventional infusion schedule |
Longer intervals in many patients |
| Main value proposition |
Established replacement therapy |
Lower infusion burden and higher trough management |
| Patent visibility |
Limited public consolidated view |
Product-specific estates often more commercially visible |
| Biosimilar risk |
Emerging after exclusivity |
Varies by product and patent estate |
| Market trajectory |
Mature or declining |
More favorable within factor replacement |
| Gene-therapy exposure |
Indirect |
Directly competes for long-term prophylaxis patients |
RIXUBIS can remain clinically useful, particularly where treatment centers have established protocols or where payer formularies favor it. Its commercial differentiation is weaker than that of products offering longer dosing intervals.
What are the likely generic launch scenarios for RIXUBIS?
The most likely scenarios are:
- No near-term biosimilar launch, with continued gradual share loss to extended-half-life products.
- A biosimilar entrant after December 2025, followed by limited initial uptake because hemophilia patients are managed through specialized treatment centers.
- Portfolio rationalization or reduced promotion by the commercial owner if revenue falls below the threshold required to support a separate brand infrastructure.
- Continued niche use in patients stable on therapy, in regions with constrained access to newer products, or under payer-specific contracts.
- Greater pressure from gene therapy for eligible adult patients, especially when payers accept outcomes-based or installment-based reimbursement.
The most plausible base case is gradual erosion rather than an abrupt generic cliff.
What is the geographic coverage of RIXUBIS?
RIXUBIS was developed for international commercialization through Baxter and later Baxalta, Shire, and Takeda. The United States is the most important disclosed regulatory market, while availability in other jurisdictions depends on local approvals, reimbursement, supply, and portfolio decisions.
Geographic risks include:
- Different biologic exclusivity periods by jurisdiction
- National reimbursement controls
- Tender-based purchasing
- Local requirements for biologic substitution
- Manufacturing and supply-chain constraints
- Variation in hemophilia treatment-center infrastructure
Market access outside the United States cannot be inferred from U.S. approval alone. The commercial product may have different availability, labeling, or distribution status by country.
Key Takeaways
- RIXUBIS is a recombinant factor IX biologic approved by the FDA on December 23, 2013.
- The product has a conventional half-life and competes against extended-half-life factor IX therapies.
- Its estimated U.S. BPCIA reference-product exclusivity endpoint is December 23, 2025.
- RIXUBIS is a Purple Book biologic, not an Orange Book small-molecule product.
- Takeda does not disclose standalone RIXUBIS revenue.
- The product’s commercial trajectory is likely mature or declining, although public reporting does not support a precise revenue estimate.
- No major publicly reported Paragraph IV litigation or settlement has materially changed the RIXUBIS market.
- The principal near-term threat is therapeutic substitution by Alprolix, Idelvion, Rebinyn, and other longer-acting products.
- Hemgenix adds a long-term gene-therapy alternative for eligible adults with hemophilia B.
- Biosimilar risk increases after December 2025 but is likely to emerge gradually because of manufacturing and treatment-center barriers.
FAQs
Is RIXUBIS still commercially available?
Commercial availability can vary by country, distributor, payer, and Takeda portfolio decisions. U.S. FDA approval remains the relevant regulatory status, but FDA approval does not guarantee continuous commercial supply in every market.
Is RIXUBIS interchangeable with Benefix?
No automatic interchangeability should be assumed. Both are recombinant factor IX products, but substitution depends on the applicable regulatory designation, payer rules, physician direction, and treatment-center protocol.
Does RIXUBIS have a biosimilar?
No RIXUBIS biosimilar has been identified as an approved U.S. product in the available FDA Purple Book record reviewed for this analysis.
Is RIXUBIS covered by orphan-drug exclusivity?
RIXUBIS was developed for hemophilia B, a rare disease. Orphan exclusivity, where applicable, is separate from BPCIA biologic exclusivity and does not create an indefinite commercial barrier.
Is RIXUBIS a gene therapy?
No. RIXUBIS is a recombinant factor IX replacement product. Hemgenix is the gene-therapy product competing in the hemophilia B market.
References
- U.S. Food and Drug Administration. (2013). RIXUBIS (coagulation factor IX recombinant) prescribing information.
- U.S. Food and Drug Administration. (2024). Regulatory information: Biosimilar and interchangeable biosimilar products.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2022). FDA approves first gene therapy for adults with hemophilia B.
- Shire plc. (2016). Annual report and accounts 2015.
- Takeda Pharmaceutical Company Limited. (2019). Acquisition of Shire plc: Completion announcement.
- Takeda Pharmaceutical Company Limited. (2024). Annual report 2024.
